Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Routy

Showing results (61-70 of 126) with videos related to

Pageof 13
Sort By:
Gut|July 13, 2021
<i>Helicobacter pylori</i> infection has a detrimental impact on the efficacy of cancer immunotherapiesPaul Oster, Laurie Vaillant, Erika Riva, et al.
Clinical and Translational Radiation Oncology|March 4, 2022
<b>S</b>tereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)Houda Bahig, Marion Tonneau, Normand Blais, et al.
Oncoimmunology|July 3, 2024
<i>Faecalibaterium prausnitzii</i> strain EXL01 boosts efficacy of immune checkpoint inhibitorsMarius Bredon, Camille Danne, Hang Phuong Pham, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study)Ramy Samaha, Rola El Sayed, Raafat Alameddine, et al.
Journal of Geriatric Oncology|January 18, 2020
Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and FranceArielle Elkrief, Corentin Richard, Julie Malo, et al.
Thrombosis Research|July 10, 2021
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort studyXavier Deschênes-Simard, Corentin Richard, Loïck Galland, et al.
BMJ Open|January 18, 2022
Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032)Stéphane Isnard, Brandon Fombuena, Jing Ouyang, et al.
Open Forum Infectious Diseases|June 30, 2021
Circulating β-d-Glucan as a Marker of Subclinical Coronary Plaque in Antiretroviral Therapy-Treated People With Human Immunodeficiency VirusStéphane Isnard, Brandon Fombuena, Manel Sadouni, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2025
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE studyPaul Wheatley-Price, Vishal Navani, Aliyah Pabani, et al.
Journal for Immunotherapy of Cancer|June 9, 2021
Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacyJulie Niogret, Hélène Berger, Cédric Rebe, et al.
Pageof 13

Showing results (61-70 of 126) with videos related to

Sort By:
Pageof 13
Gut|July 13, 2021
<i>Helicobacter pylori</i> infection has a detrimental impact on the efficacy of cancer immunotherapiesPaul Oster, Laurie Vaillant, Erika Riva, et al.
Clinical and Translational Radiation Oncology|March 4, 2022
<b>S</b>tereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)Houda Bahig, Marion Tonneau, Normand Blais, et al.
Oncoimmunology|July 3, 2024
<i>Faecalibaterium prausnitzii</i> strain EXL01 boosts efficacy of immune checkpoint inhibitorsMarius Bredon, Camille Danne, Hang Phuong Pham, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study)Ramy Samaha, Rola El Sayed, Raafat Alameddine, et al.
Journal of Geriatric Oncology|January 18, 2020
Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and FranceArielle Elkrief, Corentin Richard, Julie Malo, et al.
Thrombosis Research|July 10, 2021
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort studyXavier Deschênes-Simard, Corentin Richard, Loïck Galland, et al.
BMJ Open|January 18, 2022
Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032)Stéphane Isnard, Brandon Fombuena, Jing Ouyang, et al.
Open Forum Infectious Diseases|June 30, 2021
Circulating β-d-Glucan as a Marker of Subclinical Coronary Plaque in Antiretroviral Therapy-Treated People With Human Immunodeficiency VirusStéphane Isnard, Brandon Fombuena, Manel Sadouni, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2025
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE studyPaul Wheatley-Price, Vishal Navani, Aliyah Pabani, et al.
Journal for Immunotherapy of Cancer|June 9, 2021
Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacyJulie Niogret, Hélène Berger, Cédric Rebe, et al.
Pageof 13